Business Description
Basilea Pharmaceutica Ltd
ISIN : CH0011432447
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.47 | |||||
Equity-to-Asset | -0.06 | |||||
Debt-to-Equity | -12.86 | |||||
Debt-to-EBITDA | 5.53 | |||||
Interest Coverage | 1.96 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -4.32 | |||||
Beneish M-Score | -3.03 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.5 | |||||
3-Year Book Growth Rate | 55.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | 78.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 12.3 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 28.45 | |||||
9-Day RSI | 40.15 | |||||
14-Day RSI | 47.06 | |||||
6-1 Month Momentum % | 16.43 | |||||
12-1 Month Momentum % | -12.42 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.2 | |||||
Quick Ratio | 2.64 | |||||
Cash Ratio | 1.26 | |||||
Days Inventory | 346.43 | |||||
Days Sales Outstanding | 77.73 | |||||
Days Payable | 45.32 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.4 | |||||
Shareholder Yield % | 10.98 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 83 | |||||
Operating Margin % | 13.9 | |||||
Net Margin % | 6.63 | |||||
FCF Margin % | 8.38 | |||||
ROE % | Neg. Equity | |||||
ROA % | 5.02 | |||||
ROIC % | 17.22 | |||||
ROC (Joel Greenblatt) % | 36.42 | |||||
ROCE % | 14.96 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 69.37 | |||||
Forward PE Ratio | 21.23 | |||||
PE Ratio without NRI | 69.37 | |||||
Price-to-Owner-Earnings | 99.54 | |||||
PS Ratio | 3.58 | |||||
Price-to-Free-Cash-Flow | 50.23 | |||||
Price-to-Operating-Cash-Flow | 45.95 | |||||
EV-to-EBIT | 26.39 | |||||
EV-to-Forward-EBIT | 19.12 | |||||
EV-to-EBITDA | 24.6 | |||||
EV-to-Forward-EBITDA | 18.25 | |||||
EV-to-Revenue | 3.63 | |||||
EV-to-Forward-Revenue | 3.24 | |||||
EV-to-FCF | 44.91 | |||||
Price-to-Median-PS-Value | 0.68 | |||||
Earnings Yield (Greenblatt) % | 3.78 | |||||
FCF Yield % | 2.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return %
Total Annual Return %
Basilea Pharmaceutica Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil CHF) | 157.634 | ||
EPS (TTM) (CHF) | 0.63 | ||
Beta | 0.71 | ||
Volatility % | 29.93 | ||
14-Day RSI | 47.06 | ||
14-Day ATR (CHF) | 0.698626 | ||
20-Day SMA (CHF) | 43.137585 | ||
12-1 Month Momentum % | -12.42 | ||
52-Week Range (CHF) | 32.2 - 49 | ||
Shares Outstanding (Mil) | 12 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Basilea Pharmaceutica Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Basilea Pharmaceutica Ltd Stock Events
Event | Date | Price(CHF) | ||
---|---|---|---|---|
No Event Data |
Basilea Pharmaceutica Ltd Frequently Asked Questions
What is Basilea Pharmaceutica Ltd(LTS:0QNA)'s stock price today?
When is next earnings date of Basilea Pharmaceutica Ltd(LTS:0QNA)?
Does Basilea Pharmaceutica Ltd(LTS:0QNA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |